Knee Osteoarthritis
Conditions
Keywords
Knee Osteoarthritis
Brief summary
Central mechanisms may play a role in pain perception during osteoarthritis (OA).Local inflammation (which involves production of pro-inflammatory cytokines such as interleukin (IL) 4 TNF-alpha, IL-6 and IL-8) is considered to be a major source of pain. Certain therapies that specifically interfere with the expression or actions of pro-inflammatory cytokines have been explored. NSAIDs have analgesic, antipyretic and anti-inflammatory properties and are extensively prescribed for several musculoskeletal disorders. Indeed, the Osteoarthritis Research Society International (OARSI) recently recommended the use of NSAIDs for management of knee and hip OA in symptomatic patients. These drugs have been shown to influence cytokine metabolism in the synovial fluid of OA patients with satisfactory relief of painful osteoarthritic joints. The aim of the current study was to explore whether NSAID treatment inhibits TNF-alpha, IL-6, IL-8, and VEGF secretion in the synovial fluid of osteoarthritic joints. In particular, diclofenac, ibuprofen and celecoxib were studied. Under the hypothesis that relationships between proinflammatory cytokines and the clinical status of OA patients are possible, we also evaluated the association between the concentration of these molecules in the osteoarthritic knee synovial fluid and the pain and functional status of patients with OA. The effects of NSAIDS on signal transduction pathways in the synovial membrane were also investigated.
Detailed description
not desired
Interventions
DRUGIbuprofen
time of treatment 14 days
DRUGCelecoxib
time of treatment 14 days
DRUGDiclofenac
time of treatment 14 days
Sponsors
University of Catanzaro
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
Patients eligible for the study were: * older than 50 years and * had primary knee OA diagnosed according to the clinical and radiological criteria of the American Rheumatism Association. Further inclusion criteria were: * clinical signs of joint inflammation (warmth, swelling or effusion) and * a disease severity grade 2 or 3 according to the Kellgren-Lawrence classification
Exclusion criteria
* allergy to NSAIDs, * progressive serious medical conditions (such as cancer, AIDS or end-stage renal disease), * history of gastrointestinal ulcer or bleeding, * a hemoglobin concentration lower than 11.5 g/dL, * renal diseases (serum creatinine concentration more than 1.2 times the upper limit of the normal range according to the central laboratory definition reference values), or * liver dysfunction (serum alanine or aspartate transaminase concentrations more than 1.5 times the upper limit of normal range according to the central laboratory definition reference values).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Western Ontario and McMaster universities (WOMAC) osteoarthritis index score | 0-14 days | Womac was used to 77 measure the disease-specific health status of patients before and after the pharmacological treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Naranjo probability scale | 14 days | The Naranjo probability scale was used to evaluate the development of adverse drug reaction during this study |
Countries
Italy
Outcome results
None listed